| pubmed-article:21432843 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21432843 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:21432843 | lifeskim:mentions | umls-concept:C0007115 | lld:lifeskim |
| pubmed-article:21432843 | lifeskim:mentions | umls-concept:C0751623 | lld:lifeskim |
| pubmed-article:21432843 | lifeskim:mentions | umls-concept:C0203610 | lld:lifeskim |
| pubmed-article:21432843 | lifeskim:mentions | umls-concept:C0021149 | lld:lifeskim |
| pubmed-article:21432843 | lifeskim:mentions | umls-concept:C1514756 | lld:lifeskim |
| pubmed-article:21432843 | pubmed:issue | 19 | lld:pubmed |
| pubmed-article:21432843 | pubmed:dateCreated | 2011-9-19 | lld:pubmed |
| pubmed-article:21432843 | pubmed:abstractText | American Thyroid Association guidelines currently recommend the selective use of radioactive iodine (RAI) therapy in patients with well differentiated thyroid cancer (WDTC). Despite these guidelines, RAI ablation has been used routinely in all but the very lowest risk patients with thyroid cancer over the last 30 years. The objective of this study was to evaluate patterns of RAI use and elevated risk of secondary primary malignancies (SPM) in patients with low-risk (T1N0) WDTC. | lld:pubmed |
| pubmed-article:21432843 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21432843 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21432843 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:21432843 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21432843 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21432843 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:21432843 | pubmed:issn | 1097-0142 | lld:pubmed |
| pubmed-article:21432843 | pubmed:author | pubmed-author:GarzaG AGA | lld:pubmed |
| pubmed-article:21432843 | pubmed:author | pubmed-author:ShahaAshok... | lld:pubmed |
| pubmed-article:21432843 | pubmed:author | pubmed-author:TuttleR... | lld:pubmed |
| pubmed-article:21432843 | pubmed:author | pubmed-author:IyerN... | lld:pubmed |
| pubmed-article:21432843 | pubmed:author | pubmed-author:MorrisLuc G... | lld:pubmed |
| pubmed-article:21432843 | pubmed:copyrightInfo | Copyright © 2011 American Cancer Society. | lld:pubmed |
| pubmed-article:21432843 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21432843 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:21432843 | pubmed:volume | 117 | lld:pubmed |
| pubmed-article:21432843 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21432843 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21432843 | pubmed:pagination | 4439-46 | lld:pubmed |
| pubmed-article:21432843 | pubmed:meshHeading | pubmed-meshheading:21432843... | lld:pubmed |
| pubmed-article:21432843 | pubmed:meshHeading | pubmed-meshheading:21432843... | lld:pubmed |
| pubmed-article:21432843 | pubmed:meshHeading | pubmed-meshheading:21432843... | lld:pubmed |
| pubmed-article:21432843 | pubmed:meshHeading | pubmed-meshheading:21432843... | lld:pubmed |
| pubmed-article:21432843 | pubmed:meshHeading | pubmed-meshheading:21432843... | lld:pubmed |
| pubmed-article:21432843 | pubmed:meshHeading | pubmed-meshheading:21432843... | lld:pubmed |
| pubmed-article:21432843 | pubmed:meshHeading | pubmed-meshheading:21432843... | lld:pubmed |
| pubmed-article:21432843 | pubmed:meshHeading | pubmed-meshheading:21432843... | lld:pubmed |
| pubmed-article:21432843 | pubmed:meshHeading | pubmed-meshheading:21432843... | lld:pubmed |
| pubmed-article:21432843 | pubmed:meshHeading | pubmed-meshheading:21432843... | lld:pubmed |
| pubmed-article:21432843 | pubmed:meshHeading | pubmed-meshheading:21432843... | lld:pubmed |
| pubmed-article:21432843 | pubmed:meshHeading | pubmed-meshheading:21432843... | lld:pubmed |
| pubmed-article:21432843 | pubmed:meshHeading | pubmed-meshheading:21432843... | lld:pubmed |
| pubmed-article:21432843 | pubmed:meshHeading | pubmed-meshheading:21432843... | lld:pubmed |
| pubmed-article:21432843 | pubmed:meshHeading | pubmed-meshheading:21432843... | lld:pubmed |
| pubmed-article:21432843 | pubmed:meshHeading | pubmed-meshheading:21432843... | lld:pubmed |
| pubmed-article:21432843 | pubmed:meshHeading | pubmed-meshheading:21432843... | lld:pubmed |
| pubmed-article:21432843 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21432843 | pubmed:articleTitle | Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. | lld:pubmed |
| pubmed-article:21432843 | pubmed:affiliation | Head and Neck Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. | lld:pubmed |
| pubmed-article:21432843 | pubmed:publicationType | Journal Article | lld:pubmed |
